Adaptive Biotechnologies (ADPT) Total Liabilities (2018 - 2026)

Adaptive Biotechnologies has disclosed Total Liabilities across 9 years of filings, most recently posting $490.0 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 54.53% year-over-year to $490.0 million; the TTM figure through Jun 2026 stood at $490.0 million (up 54.53% YoY), while the FY2025 annual figure was $287.7 million, down 14.59% from the prior year.
• Total Liabilities came in at $490.0 million for Q2 2026 at Adaptive Biotechnologies, up from $281.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $490.0 million in Q2 2026 to a low of $281.7 million in Q1 2026.
• Average Total Liabilities over 5 years is $342.9 million, with a median of $340.2 million recorded in 2024.
• Year-over-year, Total Liabilities dropped 15.22% in 2022 and surged 54.53% in 2026.
• Over 5 years, Total Liabilities stood at $392.5 million in 2022, then fell by 10.1% to $352.9 million in 2023, then decreased by 4.52% to $336.9 million in 2024, then declined by 14.59% to $287.7 million in 2025, then surged by 70.3% to $490.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $490.0 million in Q2 2026, $281.7 million in Q1 2026, and $287.7 million in Q4 2025.